updated 3/24/2011 12:16:31 PM ET 2011-03-24T16:16:31

VANCOUVER, British Columbia, March 24, 2011 (GLOBE NEWSWIRE) -- biOasis Technologies Inc. (TSX-V:BTI) announces it is presenting Friday, March 25, 2011 a poster titled "A new Carrier for Delivery of Therapeutic Compounds Across the BBB for the Treatment of Brain Diseases" at the 17th annual Blood-Brain Barrier Consortium meeting held in collaboration with the International Brain Barriers Society (IBBS) being held in Stevenson, Washington.

The poster provides a summary of key scientific accomplishments achieved by the Company, including results from its recent collaborations with the University of British Columbia and the National Research Council of Canada. The data from these collaborations further demonstrated that conjugations developed under the biOasis Transcend program cross the blood-brain barrier more efficiently than is possible with other approaches, that the conjugates enter the brain tissue, and that a conjugate incorporating doxorubicin increased survival time in animal models of glioblastoma, the most common and most aggressive type of primary brain tumor in humans. A copy of the poster can be downloaded from our web site at www.bioasis.ca

"We are pleased to participate in this meeting, both as a corporate sponsor and by presenting a poster," stated Dr. Reinhard Gabathuler. "The IBBS meeting provides the opportunity to share and discuss our findings with thought leaders in the blood-brain barrier research community."

The IBBS is an international scientific and educational nonprofit organization that: encourages, promotes and advocates scientific and clinical research on the biological barriers in the central nervous system (CNS); accumulates information about barriers in the CNS and promotes its dissemination to scientists, physicians, patients, policy makers, public and private funding agencies and other concerned parties, and; educates the general public and medical profession about the existence, diagnosis and treatment of disorders involving the barriers of the CNS.

ABOUT TRANSCEND

biOasis is developing a proprietary carrier for the transport of therapeutic and imaging agents across the blood brain barrier – Transcend. Current initiatives within the Transcend program include production of materials for preclinical studies and conjugation to a range of small molecule and biologic therapeutics. To address the unmet clinical need to transport drugs across the blood brain barrier biOasis intends to license Transcend to multiple corporate partners.  

ABOUT BIOASIS:

biOasis Technologies Inc. is a biopharmaceutical company engaged in the development and commercialization of products for the diagnosis and treatment of neurological diseases and disorders. Its products and technologies are intended for use within the healthcare and life science research markets. The Company is currently developing Cognitest™, a blood test for the diagnosis of Alzheimer's disease. BiOasis is also developing Transcend, a proprietary molecular carrier intended to transport drugs across the Blood-Brain Barrier for treatment of a wide range of neurological, oncological and infectious disease applications.

Forward Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe," "may," "plan," "will," "estimate," "continue," "anticipate," "intend," "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for p97 as a Physician's Aid to Diagnose Alzheimer's, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors

R.B. (Rob) Hutchison, Chairman & CEO

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

CONTACT: R.B. (Rob) Hutchison, Chairman & CEO
         1-778-383-3280 Extension 101
         rob@bioasis.ca

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 5.04%
$30K home equity loan FICO 5.23%
$75K home equity loan FICO 4.66%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.28%
13.27%
Cash Back Cards 17.74%
17.72%
Rewards Cards 17.01%
16.98%
Source: Bankrate.com